Nabriva Therapeutics PLC (NBRVF)

[realfast95]

5/8/2018 Needham & Company LLC Reiterated Rating Buy $18.00
5/8/2018 Cantor Fitzgerald Set Price Target Buy $16.00
https://www.marketbeat.com/stocks/NASDAQ/NBRV/


Nabriva Therapeutics’ (NBRV) Buy Rating Reiterated at Needham & Company LLC

Posted by Faye Duncan on May 10th, 2018 // No Comments

Nabriva Therapeutics logoNabriva Therapeutics (NASDAQ:NBRV)‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a research report issued to clients and investors on Tuesday. They currently have a $18.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target indicates a potential upside of 282.98% from the stock’s previous close.

The analysts wrote, “Nabriva reported 1Q18 financial results today and we spoke w/ mgmt for an update. Mgmt reiterated guidance for top-line results from the second of two Phase 3 trials of lead antibiotic lefamulin in Community Pneumonia (CABP) in 2Q18. We continue to expect a positive outcome and reiterate BUY rating. We believe the opportunity for lefamulin in Community Pneumonia is misunderstood and underappreciated by investors. We acknowledge challenges for antibiotics within the hospital, but believe oral lefamulin can be relevant in the large outpatient community setting.””

https://dakotafinancialnews.com/2018/05/10/nabriva-therapeutics-nbrv-buy-rating-reiterated-at-needham-company-llc.html